144 related articles for article (PubMed ID: 36741006)
1. High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review.
Accorsi Buttini E; Farina M; Lorenzi L; Polverelli N; Radici V; Morello E; Colnaghi F; Almici C; Ferrari E; Bianchetti A; Leoni A; Re F; Bosio K; Bernardi S; Malagola M; Re A; Russo D
Front Oncol; 2023; 13():1036455. PubMed ID: 36741006
[TBL] [Abstract][Full Text] [Related]
2. Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series.
Dhaliwal A; Ravi S
Cureus; 2023 Sep; 15(9):e44677. PubMed ID: 37809221
[TBL] [Abstract][Full Text] [Related]
3. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
[TBL] [Abstract][Full Text] [Related]
4. Clonal Hematopoiesis is Associated with Severe Cytokine Release Syndrome in Patients Treated with Chimeric Antigen Receptor T-cell (CART) Therapy.
Goldsmith SR; Shouse G; Wong FL; Bosworth A; Iukuridze A; Chen S; Rhee JW; Mei M; Htut M; Janakiram M; Forman SJ; Pillai R; Budde LE; Armenian SH
Transplant Cell Ther; 2024 Jun; ():. PubMed ID: 38871057
[TBL] [Abstract][Full Text] [Related]
5. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors.
Miller A; Daum R; Wang T; Wu M; Tat C; Pfeiffer T; Navai S; Heczey A; Hegde M; Ahmed N; Whittle SB; Hill L; Martinez C; Krance R; Ramos CA; Rouce RH; Lulla P; Heslop HE; Omer B; Shekar M
Cytotherapy; 2024 May; ():. PubMed ID: 38819365
[TBL] [Abstract][Full Text] [Related]
6. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.
Zhou J; Zhang Y; Shan M; Zong X; Geng H; Li J; Chen G; Yu L; Xu Y; Li C; Wu D
Front Immunol; 2022; 13():997589. PubMed ID: 36131934
[TBL] [Abstract][Full Text] [Related]
7. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy.
Xing L; Wang Y; Liu H; Gao S; Shao Q; Yue L; Liu Z; Wang H; Shao Z; Fu R
Front Oncol; 2021; 11():798352. PubMed ID: 35004324
[TBL] [Abstract][Full Text] [Related]
9. Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report.
Liang Z; Zhang H; Shao M; Cui Q; Wu Z; Xiao L; Huang H; Hu Y
Medicine (Baltimore); 2020 Oct; 99(43):e22510. PubMed ID: 33120740
[TBL] [Abstract][Full Text] [Related]
10. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis.
Reinhardt B; Lee P; Sasine JP
Cells; 2023 Feb; 12(4):. PubMed ID: 36831198
[TBL] [Abstract][Full Text] [Related]
12. Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients.
Panagiota V; Kerschbaum JF; Penack O; Stein CM; Arends CM; Koenecke C; Strzelecka PM; Kloos A; Wiegand L; Lasch A; Altwasser R; Halik A; Gabdoulline R; Thomson J; Weibl K; Franke GN; Berger C; Hasenkamp J; Ayuk F; Na IK; Beutel G; Keller U; Bullinger L; Wulf GG; Kröger N; Vucinic V; Heuser M; Damm F
Hemasphere; 2023 Oct; 7(10):e957. PubMed ID: 37799345
[TBL] [Abstract][Full Text] [Related]
13. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
14. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
15. Safety of CAR-T Cell Therapy in Patients With Renal Failure/Acute Kidney Injury: Focused Review.
Khan I; Khan N; Wolfson N; Djebabria K; Rehman MEU; Anwer F
Clin Hematol Int; 2023 Jun; 5(2-3):122-129. PubMed ID: 37010812
[TBL] [Abstract][Full Text] [Related]
16. Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.
Shahid S; Ramaswamy K; Flynn J; Mauguen A; Perica K; Park JH; Forlenza CJ; Shukla NN; Steinherz PG; Margossian SP; Boelens JJ; Kernan NA; Curran KJ
Transplant Cell Ther; 2022 Feb; 28(2):72.e1-72.e8. PubMed ID: 34852305
[TBL] [Abstract][Full Text] [Related]
17. The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia.
Cermák J; Belicková M; Krejcová H; Michalová K; Zilovcová S; Zemanová Z; Brezinová J; Sieglová Z
Leuk Res; 2005 Apr; 29(4):371-9. PubMed ID: 15725470
[TBL] [Abstract][Full Text] [Related]
18. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Rejeski K; Perez A; Sesques P; Hoster E; Berger C; Jentzsch L; Mougiakakos D; Frölich L; Ackermann J; Bücklein V; Blumenberg V; Schmidt C; Jallades L; Fehse B; Faul C; Karschnia P; Weigert O; Dreyling M; Locke FL; von Bergwelt-Baildon M; Mackensen A; Bethge W; Ayuk F; Bachy E; Salles G; Jain MD; Subklewe M
Blood; 2021 Dec; 138(24):2499-2513. PubMed ID: 34166502
[TBL] [Abstract][Full Text] [Related]
19. Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia.
AlMozain N; Mashi A; Alneami Q; Al-Omran A; Bakshi N; Owaidah T; Khalil S; Khogeer H; Hashmi S; Al-Sweedan S; Morris T; AlNounou R
Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):39-44. PubMed ID: 33227261
[TBL] [Abstract][Full Text] [Related]
20. New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.
Wang L; Hong R; Zhou L; Ni F; Zhang M; Zhao H; Wu W; Wang Y; Ding S; Chang AH; Hu Y; Huang H
Front Oncol; 2021; 11():702644. PubMed ID: 34277448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
